MRK

Merck & Co.

$133.72

+0.69%
Nov 20, 2026
Bobby Quantitative Model
Merck & Co. is a global research-intensive pharmaceutical company whose portfolio spans oncology, vaccines, cardiometabolic and infectious disease, and animal health, with its immuno-oncology franchise led by Keytruda serving as the single largest revenue driver alongside Gardasil, ProQuad and the Winrevair pulmonary arterial hypertension launch. Merck is a top-tier big pharma incumbent rather than a disruptor — its identity rests on the scale of the Keytruda oncology franchise, a dominant vaccine business, and a large animal health unit, with roughly 53% of human health sales generated in the United States. The current investor debate centers on two opposing forces: a striking re-rating in 2026 (shares up roughly 40% over twelve months and 25% year-to-date) driven by pipeline optimism and new product ramps such as Winrevair, Capvaxive and the subcutaneous Keytruda Qlex formulation, versus a sharp late-2026 pullback of about 10% in the past month and 13% over three months. Sentiment has been complicated by a European court order favoring Halozyme that blocks Merck's subcutaneous Keytruda in that region, by a volatile earnings cadence (a Q1 loss, a Q2 loss, then a strong Q3 profit), and by the perennial overhang of Keytruda's eventual patent expiry — all of which frame the stock as a debate between near-term earnings power and long-term franchise durability.

People also watch

Eli Lilly and Company

Eli Lilly and Company

LLY

Analysis
Johnson & Johnson

Johnson & Johnson

JNJ

Analysis
AbbVie

AbbVie

ABBV

Analysis
Amgen

Amgen

AMGN

Analysis
Gilead Sciences

Gilead Sciences

GILD

Analysis

BobbyInvestment Opinion: Should I buy MRK Today?

Rating: Buy (accumulate on weakness). The core thesis is that Merck offers a 14.4x trailing / 14.8x forward earnings multiple for a 72% gross-margin franchise with a 3.10% dividend yield and $14.75B of trailing free cash flow, while a 19-Buy/0-Sell analyst consensus with a $161.53 average target implies roughly +21.6% upside from $132.81 — a favorable risk/reward after a 10.45% one-month and 12.94% three-month pullback that the sell-side has treated as an entry point rather than a thesis break.

Supporting evidence is concrete: Q3 2026 revenue of $18.085B grew 5.25% year-over-year with a 28.0% net margin and $5.065B of net income, proving operating leverage after Q1 (-$4.24B) and Q2 (-$1.335B) losses driven by R&D spikes to $12.56B and $9.74B; gross margin held in a stable 70.5%–73.5% band across all four quarters, confirming the losses were episodic rather than structural. Valuation is modest for the quality — 5.70x EV/sales, 10.59x EV/EBITDA, 4.06x PS and a 5.6% FCF yield — and the 3.10% dividend on a 44.8% payout ratio is comfortably funded by $14.75B of FCF, providing a floor that faster-growing peers lack. The 0.12 beta and 39.73% one-year return (31.70 points ahead of SPY) add a defensive quality unusual in a momentum name.

Three risks could invalidate the thesis: the Halozyme European injunction blocking subcutaneous Keytruda, Keytruda-plus-Qlex concentration at ~47.6% of quarterly revenue, and the lumpy earnings cadence that leaves trailing EPS at just $0.069. The rating would upgrade toward a stronger Buy if Q4 confirms the Q3 recovery and the stock reclaims the $150 level, and would downgrade to Hold if the stock breaks decisively below the $130 support shelf or if the European injunction is mirrored in other jurisdictions. On balance the stock is fairly valued to modestly undervalued relative to its own 9x–24x historical PE band (currently 14.4x, near the midpoint) and at a discount to sector mid-to-high-teens to low-twenties multiples — the discount is justified by concentration and legal risk, but not by the full $81 spread between the $105 low and $186 high targets.

Sign up to view all

MRK 12-Month Price Forecast

The forward view is constructive but not complacent: Merck's 14.4x trailing PE and 14.8x forward PE price in flat near-term earnings, so the Q3 snap-back to a 28.0% net margin on $18.085B of revenue (up 5.25% year-over-year) is the evidence that the losses were episodic rather than structural. The 19-Buy/0-Sell consensus and $161.53 average target imply +21.6% upside, and the sell-side's refusal to capitulate through a 10.45% one-month decline suggests the pullback is being treated as an entry point. The wide $105–$186 target spread is the market pricing the Keytruda durability and Halozyme injunction binary, which is why confidence is medium rather than high despite the attractive multiple. An upgrade to high confidence would follow a Q4 print confirming the Q3 margin and a resolution of the European dispute; a downgrade to neutral would follow a break below the $130 support shelf or replication of the injunction in other jurisdictions.

Historical Price
Current Price $133.72
Average Target $150.76
High Target $186.00
Low Target $105.00

Wall Street consensus

Most Wall Street analysts maintain a constructive view on Merck & Co.'s 12-month outlook, with a consensus price target around $161.53 and implied upside of +20.8% versus the current price.

Average Target

$161.53

28 analysts

Implied Upside

+20.8%

vs. current price

Analyst Count

28

covering this stock

Price Range

$105 - $186

Analyst target range

Buy
19 (68%)
Hold
9 (32%)
Sell
0 (0%)

Coverage is deep and predominantly bullish: 26 analysts cover Merck with a distribution of 19 Buy, 9 Hold and 0 Sell, yielding a consensus recommendation of "buy" and a recommendation mean of 1.82 (where 1.0 is a strong buy). The average target price of $161.53 implies roughly +21.6% upside from the current $132.81, and the consensus 2027 EPS estimate of $9.82 with revenue of $74.85 billion (range $73.50–$76.73 billion) supports the view that analysts see the Q3 profit recovery as durable rather than a one-off. The bullish tilt is notable given the stock's 10.4% one-month decline — the sell-side has not capitulated, suggesting the pullback is viewed as an entry opportunity rather than a thesis break.

The target range of $105 to $186 is wide — a spread of $81, or roughly 61% of the current price — signaling meaningful disagreement about the Keytruda franchise's durability and the impact of the Halozyme European injunction. The $186 high target likely assumes multiple expansion toward 19x forward earnings, successful subcutaneous Keytruda launches outside Europe, and continued Winrevair and vaccine ramps; the $105 low target prices in margin compression, legal setbacks and a faster erosion of the oncology franchise. Recent institutional actions show stability rather than momentum — Guggenheim, JP Morgan, Barclays and Morgan Stanley maintain Buy/Overweight ratings while Cantor Fitzgerald, RBC and Citigroup stay Neutral, with no upgrades or downgrades in the October–November 2026 window — implying conviction is high but repositioning is dormant, and the wide dispersion means position sizing should account for binary legal and pipeline catalysts.

Drowning in data?

Find the real signal!

Bulls vs Bears: MRK Investment Factors

The bear case currently has stronger near-term price evidence — a 10.45% one-month and 12.94% three-month decline, a break from the August $156.45 peak, and a fresh legal setback in Europe — but the bull case has stronger fundamental and valuation evidence, with a 19-Buy/0-Sell analyst consensus, +21.6% average target upside, a 14.42x PE at a sector discount, and a Q3 profit snap-back that validates the underlying 72% gross-margin economics. The single most important tension is Keytruda franchise durability: at ~47.6% of revenue, how the patent cliff and the Halozyme European injunction resolve will determine whether Merck re-rates toward the $186 high target (implying ~19x forward earnings) or compresses toward the $105 low target. The wide $81 target spread is the market's way of pricing this binary, and it means position sizing must account for legal and pipeline catalysts rather than treating Merck as a low-variance defensive holding despite its 0.12 beta.

Bullish

  • Analyst consensus firmly bullish with 21.6% upside: Of 26 covering analysts, 19 rate Buy and none rate Sell, producing a recommendation mean of 1.82 and an average target of $161.53 versus the current $132.81 — roughly +21.6% implied upside. Critically, this bullish tilt has held through a 10.4% one-month decline, indicating the sell-side views the pullback as an entry point rather than a thesis break.
  • Q3 profit snap-back proves operating leverage: After Q1 (-$4.24B) and Q2 (-$1.335B) losses driven by R&D spikes to $12.56B and $9.74B, Q3 2026 delivered $5.065B of net income on a 28.0% net margin as R&D normalized to $4.54B. Gross margin stayed remarkably stable in the 70.5%–73.5% band across all four quarters, confirming the losses were episodic charges rather than structural margin erosion.
  • Cheap multiple with a dividend floor: At 14.42x trailing and 14.81x forward earnings, Merck trades at a discount to the drug manufacturers sector's typical mid-to-high-teens to low-twenties multiples, with a 5.70x EV/sales and 10.59x EV/EBITDA that are modest for a 72% gross-margin franchise. The 3.10% dividend yield on a 44.8% payout ratio, funded comfortably by $14.75B trailing FCF, provides a valuation floor faster-growing peers lack.
  • Diversified growth engines beyond Keytruda: While Keytruda ($7.771B) plus Keytruda Qlex ($830M) represent ~47.6% of quarterly revenue, the remaining base is broad: Gardasil/Gardasil 9 at $1.995B, Winrevair at $694M, and animal health (Livestock $1.048B, Companion Animal $628M). Q3 revenue grew 5.25% YoY to $18.085B, and the trailing four quarters show a consistent upward cadence from the $15.6–$17.2B range of 2025.

Bearish

  • Momentum has cracked sharply: The stock is down 10.45% over one month and 12.94% over three months, including a -3.61% single-session drop to $132.81 on 13.5 million shares, versus a +39.73% one-year gain. It now sits 15.4% below its $156.92 52-week high and trails SPY by 3.53 points over one month and 6.43 points over three months — classic leadership fading at the margin.
  • Keytruda concentration is the core fragility: Keytruda plus Qlex at ~47.6% of quarterly revenue means nearly half the top line depends on a single oncology franchise facing eventual patent expiry. This concentration is precisely why the stock trades at 14.42x earnings rather than sector-premium multiples, and it is the single factor that most determines long-term franchise durability.
  • Halozyme European injunction blocks subQ Keytruda: A European court order favoring Halozyme blocks Merck's subcutaneous Keytruda in that region, directly undercutting one of the key pipeline growth narratives (the Qlex formulation). The $81 spread between the $105 low and $186 high analyst targets — roughly 61% of the current price — reflects genuine disagreement about how much this legal setback damages the franchise.
  • Earnings are lumpy and R&D-heavy: Two of the last three quarters were losses, with Q1 2026 R&D spiking to $12.56B and Q2 to $9.74B, producing net margins of -26.03% and -8.04% respectively. The trailing EPS of $0.069 is heavily distorted, and the tight 14.42x trailing versus 14.81x forward PE gap implies the market expects essentially flat near-term earnings rather than reacceleration.

MRK Technical Analysis

Merck is in a powerful primary uptrend that has recently cracked: the stock is up 39.73% over the past year and 24.76% year-to-date, but the current price of $132.81 sits at roughly 61.7% of its 52-week range of $93.90 to $156.92, meaning it has surrendered a meaningful portion of its highs after peaking at $156.45 in late August. That positioning — well above the 52-week low but about 15.4% below the 52-week high — is consistent with the reported max drawdown of -15.11%, signaling a momentum name that has shifted from breakout mode into a corrective phase rather than a broken long-term trend. The 52-week low of $93.90 implies the stock has nearly doubled off its trough, so the current consolidation is best read as profit-taking within an uptrend rather than a falling knife.

Short-term momentum is clearly decelerating and now diverging from the longer-term trend: the stock is down 10.45% over the past month and 12.94% over three months, versus a 39.73% one-year gain, and the most recent session alone saw a -3.61% drop from $137.78 to $132.81 on 13.5 million shares. This divergence — a strong 12-month trend colliding with a negative 1-month and 3-month slope — typically signals either a trend reversal or a deeper mean-reversion pullback, and the fact that the 6-month change remains +8.50% suggests the damage is concentrated in the last quarter rather than the last half-year. Relative strength confirms the deterioration: MRK trails SPY by 3.53 points over one month and 6.43 points over three months, even though it still leads by 31.70 points over twelve months and 19.78 points year-to-date, a classic pattern of leadership fading at the margin.

Key technical levels are now well defined: support sits at the $130 area (the July/August breakout shelf around $130.20–$131.82) with secondary support at the 52-week low of $93.90, while resistance is the $156.92 52-week high and the $152–$156 congestion zone from August. A decisive break below $130 would risk a retest of the $120–$125 June/July base, whereas reclaiming $150 would reassert the uptrend toward the highs. Volatility context is unusual: the reported beta of 0.12 implies the stock has historically moved with only about 12% of the market's volatility, an extraordinarily low sensitivity that argues for smaller-than-index position sizing adjustments but also means idiosyncratic, stock-specific news — such as the Halozyme European injunction — can dominate price action far more than broad market moves.

Beta

0.12

0.12x market volatility

Max Drawdown

-15.1%

Largest decline past year

52-Week Range

$96-$157

Price range past year

Annual Return

+40.8%

Cumulative gain past year

PeriodMRK ReturnS&P 500
1m-10.8%-9.7%
3m-12.3%-9.9%
6m+9.2%-7.5%
1y+40.8%+4.7%
ytd+25.6%+1.2%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

MRK Fundamental Analysis

Revenue is growing steadily rather than spectacularly: Q3 2026 revenue of $18.085 billion rose 5.25% year-over-year versus $17.183 billion in Q3 2025, and the trailing four quarters ($18.085B, $16.607B, $16.286B, $16.324B) show a consistent upward cadence from the $15.6–$17.2 billion quarterly range of 2025. Segment data reveal the growth engine is concentrated: Keytruda at $7.771 billion plus Keytruda Qlex at $830 million together represent roughly 47.6% of quarterly revenue, with Gardasil/Gardasil 9 at $1.995 billion, Winrevair at $694 million, and the animal health franchise (Livestock $1.048 billion, Companion Animal $628 million) providing diversification. The implication is a high-quality but concentrated growth story — the 5.25% top-line growth is respectable for a mega-cap pharma, but the dependence on a single oncology franchise is precisely what keeps the valuation multiple compressed relative to faster-growing peers.

Profitability is strong but lumpy: Q3 2026 net income was $5.065 billion on a 72.95% gross margin and 28.01% net margin, yet the prior two quarters were losses — Q2 2026 at -$1.335 billion (-8.04% net margin) and Q1 2026 at -$4.240 billion (-26.03% net margin) — driven by a Q1 R&D spike to $12.558 billion and a Q2 R&D level of $9.741 billion, versus a more normalized $4.537 billion in Q3. Gross margin has been remarkably stable in the 70.5%–73.5% band across the last four quarters, and the 36.17% operating margin and 71.98% gross margin in the key metrics confirm that the underlying business economics remain intact; the losses reflect episodic charges and acquisition-related spending rather than structural margin compression. For big pharma, a ~72% gross margin and high-20s net margin are solidly in line with industry norms, and the Q3 snap-back demonstrates operating leverage when R&D normalizes.

Balance sheet and cash generation are healthy but not fortress-like: debt-to-equity stands at 0.96, the current ratio at 1.54, and trailing free cash flow is $14.746 billion, with Q3 2026 FCF of $5.518 billion on operating cash flow of $6.558 billion against $1.040 billion of capex. ROE of 34.70% and ROA of 11.29% are strong, and the company comfortably funds its $2.099 billion quarterly dividend (payout ratio 44.8%, yield 3.10%) plus buybacks ($653 million in Q3) from internal cash — though Q1 2026 saw $8.779 billion of acquisitions and a $9.292 billion cash drawdown, showing Merck will lean on M&A and external capital allocation to offset the eventual Keytruda cliff. The FCF yield of roughly 5.6% on the $263 billion market cap and the 0.96 leverage ratio indicate moderate financial risk: ample liquidity and cash generation, but a balance sheet that is being actively deployed rather than hoarded.

Quarterly Revenue

$18.1B

2026-09

Revenue YoY Growth

+4.7%

YoY Comparison

Gross Margin

73.0%

Latest Quarter

Free Cash Flow

$14.7B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Keytruda
Keytruda Qlex
Alliance revenue-Lynparza
Alliance revenue-Lenvima
Welireg
Alliance revenue-Reblozyl
Gardasil/Gardasil 9
ProQuad/M-M-R II/Varivax
Bridion
Prevymis
Capvaxive
Vaxneuvance
RotaTeq
Zerbaxa
Delstrigo
Enflonsia
Isentress/Isentress HD
Dificid
Lagevrio
Winrevair
Januvia
Janumet
Ohtuvayre
Alliance revenue-Adempas/Verquvo
Adempas
Other pharmaceutical
Livestock
Companion Animal
Other

Open an Account, get $2 TSLA now!

Valuation Analysis: Is MRK Overvalued?

Because net income is positive on a trailing basis (EPS of $0.069 is distorted by the Q1/Q2 losses but trailing net income is positive), the PE ratio is the appropriate primary metric, and Merck trades at 14.42x trailing and 14.81x forward earnings — an unusually tight gap that implies the market expects essentially flat near-term earnings rather than a growth reacceleration. The forward PE of 14.81x against consensus 2027 EPS of $9.82 suggests the market is pricing Merck as a mature, cash-generative pharma with limited multiple expansion potential, and the PEG ratio of 1.81 and price-to-cash-flow of 15.99 reinforce a value-oriented rather than growth-oriented framing.

Against the drug manufacturers — general industry, Merck's 14.42x trailing PE and 4.06x PS sit at a discount to the sector's typical mid-to-high-teens to low-twenties multiples, and its 5.70x EV/sales and 10.59x EV/EBITDA are modest for a company with 72% gross margins and a dominant oncology franchise. The 5.01x price-to-book looks elevated only because of a high equity multiplier (2.96x) and aggressive buybacks that shrink book value; on earnings and cash flow, Merck screens as a relative value. The discount is arguably justified by Keytruda concentration risk and the Halozyme European injunction headline, but the 3.10% dividend yield and 44.8% payout ratio provide a valuation floor that faster-growing peers lack.

Historically, Merck's own PE band has ranged from roughly 9x to 24x over the past several years, with the current 14.42x sitting near the middle of that range — above the 9.04x trough of Q3 2025 but well below the 21.9x–23.3x levels seen in late 2025 and 2022. The PS ratio of 4.06x is near the low end of its historical 12x–21x range on the quarterly historical ratios series, though that series appears to use a different share-count basis and should be treated directionally. Net-net, the stock is neither at a historical extreme cheap nor expensive: the market is pricing in modest expectations, leaving room for re-rating if Q4 confirms the Q3 earnings recovery and if pipeline assets such as Winrevair and subcutaneous Keytruda offset competitive and legal headwinds.

PE

14.4x

Latest Quarter

vs. Historical

Mid-Range

5-Year PE Range 9x~24x

vs. Industry Avg

18.6x

Industry PE ~18.6x*

EV/EBITDA

10.6x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks center on revenue concentration and earnings volatility. Keytruda plus Qlex represent roughly 47.6% of quarterly revenue ($7.771B + $830M of $18.085B), so any competitive or legal erosion of that franchise hits nearly half the top line directly. Earnings are genuinely lumpy — Q1 2026 lost $4.24B and Q2 lost $1.335B on R&D spikes to $12.56B and $9.74B — and while Q3's $5.065B profit on a 28.0% net margin shows recovery, the trailing EPS of $0.069 is heavily distorted and offers thin cushion. Debt-to-equity of 0.96 and a current ratio of 1.54 are adequate but not fortress-like, and Q1's $8.779B of acquisitions plus a $9.292B cash drawdown show the balance sheet is being actively deployed to offset the eventual Keytruda cliff, adding integration and capital-allocation risk.

Market and competitive risks are dominated by the Halozyme European injunction blocking subcutaneous Keytruda, which directly threatens a key growth narrative and helps explain the $81 spread between the $105 low and $186 high analyst targets. Valuation compression risk is real despite the modest 14.42x trailing PE: the stock re-rated roughly 40% over twelve months and 24.76% year-to-date, and a 14.42x trailing versus 14.81x forward PE gap signals the market expects flat near-term earnings, leaving little multiple cushion if growth disappoints. The 0.12 beta means broad macro moves matter little, but it also means idiosyncratic news — legal rulings, pipeline data, Keytruda competition — dominates price action far more than index direction, and the recent 3.53-point one-month and 6.43-point three-month underperformance versus SPY shows that stock-specific risk is already being priced.

Worst-case scenario: a European injunction expands or is mirrored in other jurisdictions, subcutaneous Keytruda launches stall, and a competitor erodes the core Keytruda franchise faster than pipeline assets like Winrevair ($694M) and Capvaxive can offset. Combined with margin compression and analyst downgrades, this is the path to the $105 low target — a decline of roughly 21% from the current $132.81. A deeper retest toward the $93.90 52-week low would represent approximately -29% downside, and the stock's -15.11% max drawdown shows how quickly a corrective phase can deepen; investors should size positions assuming a realistic -20% to -30% adverse outcome in a thesis-break scenario.

FAQ

Ranked by severity: first, franchise concentration — Keytruda at $7.771B plus Keytruda Qlex at $830M represent roughly 47.6% of the $18.085B quarterly revenue, so competitive or legal erosion of that single oncology franchise hits nearly half the top line and is the main reason the stock trades at 14.42x rather than sector-premium multiples. Second, legal/company-specific risk — the Halozyme European court order blocking subcutaneous Keytruda directly undercuts a key growth narrative and helps explain the $81 spread between the $105 low and $186 high analyst targets. Third, earnings volatility — Q1 2026 lost $4.24B and Q2 lost $1.335B on R&D spikes to $12.56B and $9.74B, leaving trailing EPS at just $0.069 and thin cushion if charges recur. Fourth, valuation and momentum risk — after a 39.73% one-year and 24.76% year-to-date re-rating, the stock is down 10.45% in a month and 12.94% in three months, trailing SPY by 3.53 and 6.43 points respectively, and a break below the $130 shelf could accelerate selling toward $120–$125. Macro risk is comparatively minor given the 0.12 beta, but that same low beta means idiosyncratic news dominates price action.

The 12-month view splits three ways: a 50% base case of $140–$161.53 assuming 2027 EPS near the $9.82 consensus and revenue near $74.85B, gross margin holding in the 70.5%–73.5% band, and the Halozyme injunction staying Europe-only while the $130 shelf holds; a 25% bull case of $161.53–$186 requiring durable Q3-style profitability, multiple expansion toward 16.5x–19x forward earnings, and resolution or containment of the European dispute; and a 25% bear case of $105–$120 if the injunction expands, subcutaneous Keytruda launches stall, and a competitor erodes the core franchise faster than Winrevair ($694M) and Capvaxive can offset. The base case is most likely and its key assumption is that the Q3 net margin of 28.0% on $18.085B of revenue proves episodic-recovery rather than a one-off, with R&D normalizing near $4.5B per quarter. Note the wide $81 target spread — roughly 61% of the current price — which is the market pricing the Keytruda durability and legal binary rather than a single consensus outcome.

On the primary metric, Merck screens modestly undervalued: 14.42x trailing and 14.81x forward earnings versus a sector that typically trades in the mid-to-high-teens to low-twenties, with 5.70x EV/sales, 10.59x EV/EBITDA and a 5.6% free cash flow yield on $14.75B of trailing FCF. The unusually tight trailing-to-forward PE gap (14.42x vs. 14.81x) tells you the market expects essentially flat near-term earnings rather than reacceleration, which is a modest-expectations setup rather than a stretched one. Against its own history, Merck's PE band has run roughly 9x to 24x, so 14.42x sits near the midpoint — above the 9.04x trough of Q3 2025 but well below the 21.9x–23.3x levels of late 2025 and 2022. The 5.01x price-to-book looks high only because of a 2.96x equity multiplier and buybacks that shrink book value; on earnings and cash flow the stock is a relative value. The discount to peers is justified by Keytruda concentration and the European legal overhang, but the 3.10% yield and 44.8% payout ratio provide a floor — the market is pricing modest expectations, leaving room for re-rating if Q4 confirms the Q3 recovery.

From a risk/reward standpoint the setup is favorable but not risk-free: at $132.81 the stock sits roughly 21.6% below the $161.53 average analyst target, with 19 Buy ratings and zero Sells among 26 analysts, while trading at 14.42x trailing and 14.81x forward earnings — a discount to the drug manufacturers sector's typical mid-to-high-teens to low-twenties multiples. The downside is quantifiable: the $105 low analyst target implies about -21% and a retest of the $93.90 52-week low would mean roughly -29%, so the reward-to-risk is roughly 1:1 against the average target and better only if the bull case toward $186 (+40%) plays out. The biggest single risk is the Halozyme European injunction blocking subcutaneous Keytruda, compounded by the fact that Keytruda plus Qlex are ~47.6% of quarterly revenue. It is a good buy for patient, income-oriented investors comfortable with a 3.10% dividend yield and a 0.12 beta who can tolerate a 20%–30% adverse scenario, particularly on further weakness toward the $130 support shelf; it is less suitable for investors who need near-term momentum, given the 10.45% one-month and 12.94% three-month declines.

Merck is structurally a long-term holding: it is a mature, cash-generative big pharma with $14.75B of trailing free cash flow, a 3.10% dividend on a comfortable 44.8% payout ratio, a 0.12 beta, and a 34.70% ROE, which suits multi-year ownership aimed at compounding plus income rather than trading. The near-term picture argues against short-term entry chasing — the stock is down 10.45% over one month and 12.94% over three months, sits 15.4% below its $156.92 high, and has a -15.11% max drawdown, so momentum traders face a corrective phase with defined levels ($130 support, $150 resistance) rather than a clean trend. Earnings visibility is impaired by the lumpy cadence (two losses in the last three reported quarters) and by binary legal catalysts, which raises the required holding period for the thesis to play out. A reasonable minimum holding period is 18–24 months — long enough to see the Q4 2026 confirmation, the 2027 EPS delivery toward $9.82, and resolution of the Halozyme European dispute — with position sizing that assumes a realistic -20% to -30% adverse outcome in a thesis-break scenario.